Response to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLC

被引：0
|
作者：
Rothschild, S. I. [1 ]
Leger, P. [2 ]
Castellanos, E. L. [2 ]
Pillai, R. N. [3 ]
York, S. J. [2 ]
Horn, L. [2 ]
机构：
[1] Univ Spital Basel, Dept Internal Med, Med Oncol, Basel, Switzerland
[2] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA
[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
91PD-PR
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Whole Body PD-1 and PD-L1 PET in Pts with NSCLC
    Niemeijer, A.
    Smit, E.
    Van Dongen, G.
    Windhorst, A. D.
    Huisman, M.
    Hendrikse, N.
    Bahce, I.
    Lueng, D.
    Smith, R.
    Hayes, W.
    Wilson, L.
    Bonacorsi, S.
    Donnelly, D.
    Morin, P.
    Poot, A.
    Vugts, D.
    Thunnissen, E.
    De Langen, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1817 - S1817
  • [42] Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
    Jelinek, Tomas
    Paiva, Bruno
    Hajek, Roman
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [43] Progress on biphenyl derivatives as PD-1/PD-L1 inhibitors
    Shurong Wang
    Yuli Wang
    Hong Yan
    Medicinal Chemistry Research, 2023, 32 : 2089 - 2115
  • [44] Potential effects of olanzapine: Enhancing the immune response to PD-1/PD-L1 inhibitors
    Yi, Y. L.
    Huang, L.
    Huang, P.
    Chen, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S706 - S706
  • [45] Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
    Diggs, Laurence P.
    Hsueh, Eddy C.
    BIOMARKER RESEARCH, 2017, 5
  • [46] Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
    Laurence P. Diggs
    Eddy C. Hsueh
    Biomarker Research, 5
  • [47] Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer
    Yao, W.
    Zhao, X.
    Gong, Y.
    Zhang, M.
    Zhang, L.
    Wu, Q.
    Wu, L.
    Fan, Z.
    Yan, X.
    Jiao, S.
    ESMO OPEN, 2021, 6 (02)
  • [48] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
    Duruisseaux, Michael
    Rouquette, Isabelle
    Adam, Julien
    Cortot, Alexis
    Cazes, Aurelie
    Gibault, Laure
    Damotte, Diane
    Lantuejoul, Sylvie
    ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
  • [49] Beyond inhibition against the PD-1/PD-L1 pathway: development of PD-L1 inhibitors targeting internalization and degradation of PD-L1
    Guo, Jiazheng
    Yu, Fengyi
    Zhang, Kuojun
    Jiang, Sheng
    Zhang, Xiangyu
    Wang, Tianyu
    RSC MEDICINAL CHEMISTRY, 2024, 15 (04): : 1096 - 1108
  • [50] Inside PD-1/PD-L1,2 with their inhibitors
    Boisgerault, Nicolas
    Bertrand, Philippe
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 256
12345